University of Florida at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
University of Florida brings 3 presentations to ESGCT 2026 in Hamburg. Its contributions pair basic AAV capsid structure, including the capsid interactome and newly described variants, with clinical translation. The clinical strand reports one-year safety and pharmacodynamic results from an early-stage study in children with limb-girdle muscular dystrophy type R5.
| Organization | ESGCT 2026 Attendance |
|---|---|
University of Florida Gainesville, FL | |
Home of the Powell Gene Therapy Center, long active in AAV vector biology and clinical gene therapy. | Talk Tue Oct 27 5:00pm–7:30pm Structural characterization of the AAV capsid interactome Vectors and delivery (AAV, lentiviral, LNP) Poster Thu Oct 29 2:00pm–4:00pm The structural and antigenic characterization of AAVra.1 and AAVmo.1 capsids Talk Fri Oct 30 10:00am–10:30am Early Results From an Interventional Phase 1 Pediatric Study of ATA‑200 Gene Therapy in LGMD-R5 Demonstrate Favorable Safety and Pharmacodynamic Activity at One Year Rare and inherited diseaseClinical trials and translation |
Instantly find 20 buyers from University of Florida
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction